SCHEMBL3760324

SCHEMBL3760324

COc1ccc(-c2nc(-c3ccccc3)[nH]c2C(=O)O)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.73
ALDH1A1 P00352 6/20 0.73
HPGD P15428 5/20 0.73
KMT2A Q03164 5/20 0.73
MAPT P10636 4/20 0.73
MEN1 O00255 4/20 0.73
GLA P06280 3/20 0.73
GAA P10253 3/20 0.73
CYP1A2 P05177 2/20 0.73
CYP2C19 P33261 2/20 0.73
GFER P55789 1/20 0.73
TP53 P04637 2/20 0.66
RAF1 P04049 2/20 0.62
MAPK13 O15264 1/20 0.62
MAPK12 P53778 1/20 0.62
MAPK11 Q15759 1/20 0.62
MAPK14 Q16539 1/20 0.62
NOX1 Q9Y5S8 1/20 0.57
PIN1 Q13526 2/20 0.54
MAPK1 P28482 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3119934 0.89 MAPK13 (0.67) KDM4EALDH1A1HPGDKMT2AMAPT
SCHEMBL3120707 0.89 KDM4E (0.62) KDM4EALDH1A1HPGDKMT2AMAPT
SCHEMBL3120984 0.85 MAPT (0.58) KDM4EALDH1A1HPGDKMT2AMAPT
SCHEMBL3120095 0.83 NOX1 (0.56) KDM4EALDH1A1HPGDKMT2AMAPT
SCHEMBL7143433 0.82 MAPT (0.64) KDM4EALDH1A1HPGDKMT2AMAPT
SCHEMBL15400046 0.82 MAPK13 (0.86) KDM4EALDH1A1HPGDKMT2AMAPT
SCHEMBL1132001 0.82 MAPK13 (0.86) KDM4EALDH1A1HPGDKMT2AMAPT
SCHEMBL1308320 0.82 MAPK13 (0.86) KDM4EALDH1A1HPGDKMT2AMAPT
SCHEMBL8104080 0.82 MAPK13 (0.86) KDM4EALDH1A1HPGDKMT2AMAPT
SCHEMBL4504351 0.81 MAPK13 (0.59) KDM4EALDH1A1HPGDKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9187465-B2 Oxazole tyrosine kinase inhibitors SAREUM LIMITED (GB) 2015-11-17 US disclosed
US-20150057282-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2015-02-26 US disclosed
US-8921544-B2 Oxazole tyrosine kinase inhibitors SAREUM LIMITED (GB) 2014-12-30 US disclosed
US-20140275041-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2014-09-18 US disclosed
US-20130102592-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2013-04-25 US disclosed
US-8378095-B2 Oxazole tyrosine kinase inhibitors Saruem Limited (GB) 2013-02-19 US disclosed
US-20100298301-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275041-A1 OXAZOLE TYROSINE KINASE INHIBITORS FLT3, AURKA, FLT1 KDM4E 718/4885ALDH1A1 1403/4885HPGD 4701/4885
US-20100298301-A1 OXAZOLE TYROSINE KINASE INHIBITORS FLT3, AURKA, FLT1 KDM4E 718/4885ALDH1A1 1403/4885HPGD 4701/4885
US-20150057282-A1 OXAZOLE TYROSINE KINASE INHIBITORS FLT3, AURKA, FLT1 KDM4E 718/4885ALDH1A1 1403/4885HPGD 4701/4885
US-20130102592-A1 OXAZOLE TYROSINE KINASE INHIBITORS FLT3, AURKA, FLT1 KDM4E 675/4885ALDH1A1 1431/4885HPGD 4686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.